Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

• DOI: 10.1200/jco.1998.16.7.2452
• Publication Date: 2017-02-24T10:01:01Z
• Authors: P A Meyers; R Gorlick; G Heller; E Casper; J Lane; A G Huvos; J H Healey
• Keywords: Regimen; Chemotherapy regimen

PURPOSE It has been observed previously in osteosarcoma (OS) that the degree of necrosis resected primary tumor following a period preoperative chemotherapy is predictive subsequent event-free survival (EFS). The aim this study was to determine if more intensive would increase proportion patients with good histologic response and improve EFS. PATIENTS AND METHODS Seventy-three OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on T12 protocol between 1986 1993. Patients randomized therapy based T10 chemotherapy. regimen consisted two courses cisplatin (CDDP) doxorubicin (DOX) addition usual high-dose methotrexate (HD MTX) bleomycin, cyclophosphamide, dactinomycin (BCD). RESULTS achieved modest (44% grade III or IV v 37% control arm, 33% 13% arm). EFS continued correlate response. actuarial 5-year localized disease 78% for 73% arm. CONCLUSION Despite increases intensified chemotherapy, no improvement observed.